Howitt A, Armstrong D
Warders Medical Centre, Tonbridge, Kent TN9 1LA.
BMJ. 1999 May 15;318(7194):1324-7. doi: 10.1136/bmj.318.7194.1324.
To determine the extent to which implementation of an evidence based treatment, antithrombotic treatment in atrial fibrillation, is possible in general practice.
Audit and qualitative study of patients with atrial fibrillation and an educational intervention for patients judged eligible for antithrombotic treatment.
South east England.
56 patients with a history of atrial fibrillation.
Assessment and interview to ascertain patients' views on antithrombotic treatment.
Number of patients receiving antithrombotic treatment.
Out of 13 239 patients, 132 had a history of atrial fibrillation of which 100 were at risk of thromboembolism. After the study, 52 patients were taking warfarin. Of the remaining 48 patients (of whom 41 were taking aspirin), eight were too ill to participate, 16 were unable to consent, four refused the interview, and 20 declined warfarin. Patients declining warfarin were inclined to seek a higher level of benefit than those taking it, as measured by the minimal clinically important difference. Qualitative data obtained during the interviews suggested that patients' health beliefs were important factors in determining their choice of treatment.
Patients' unwillingness to take warfarin seemed to be a major factor in limiting the number who would eventually take it.
确定在基层医疗中实施基于证据的治疗方法(心房颤动的抗血栓治疗)的可行程度。
对心房颤动患者进行审计和定性研究,并对被判定适合抗血栓治疗的患者进行教育干预。
英格兰东南部。
56例有房颤病史的患者。
进行评估和访谈,以确定患者对抗血栓治疗的看法。
接受抗血栓治疗的患者数量。
在13239例患者中,132例有房颤病史,其中100例有血栓栓塞风险。研究结束后,52例患者正在服用华法林。其余48例患者(其中41例正在服用阿司匹林)中,8例病情过重无法参与,16例无法签署知情同意书,4例拒绝访谈,20例拒绝服用华法林。通过最小临床重要差异衡量,拒绝服用华法林的患者比服用华法林的患者倾向于寻求更高水平的获益。访谈期间获得的定性数据表明,患者的健康观念是决定其治疗选择的重要因素。
患者不愿服用华法林似乎是限制最终服用该药人数的主要因素。